Please use this identifier to cite or link to this item:
|Title:||mTORC1 inhibition restricts infammation-associated gastrointestinal tumorigenesis in mice||Authors:||Thiem, S.
|Issue Date:||1-Feb-2013||Citation:||Thiem, S., Pierce, T.P., Palmieri, M., Putoczki, T.L., Buchert, M., Preaudet, A., Farid, R.O., Love, C., Catimel, B., Lei, Z., Rozen, S., Gopalakrishnan, V., Schaper, F., Hallek, M., Boussioutas, A., Tan, P., Jarnicki, A., Ernst, M. (2013-02-01). mTORC1 inhibition restricts infammation-associated gastrointestinal tumorigenesis in mice. Journal of Clinical Investigation 123 (2) : 767-781. ScholarBank@NUS Repository. https://doi.org/10.1172/JCI65086||Abstract:||Gastrointestinal cancers are frequently associated with chronic inflammation and excessive secretion of IL-6 family cytokines, which promote tumorigenesis through persistent activation of the GP130/JAK/STAT3 pathway. Although tumor progression can be prevented by genetic ablation of Stat3 in mice, this transcription factor remains a challenging therapeutic target with a paucity of clinically approved inhibitors. Here, we uncovered parallel and excessive activation of mTOR complex 1 (mTORC1) alongside STAT3 in human intestinal-type gastric cancers (IGCs). Furthermore, in a preclinical mouse model of IGC, GP130 ligand administration simultaneously activated mTORC1/S6 kinase and STAT3 signaling. We therefore investigated whether mTORC1 activation was required for inflammation-associated gastrointestinal tumorigenesis. Strikingly, the mTORC1-specific inhibitor RAD001 potently suppressed initiation and progression of both murine IGC and colitis-associated colon cancer. The therapeutic effect of RAD001 was associated with reduced tumor vascularization and cell proliferation but occurred independently of STAT3 activity. We analyzed the mechanism of GP130-mediated mTORC1 activation in cells and mice and revealed a requirement for JAK and PI3K activity but not for GP130 tyrosine phosphorylation or STAT3. Our results suggest that GP130-dependent activation of the druggable PI3K/mTORC1 pathway is required for inflammation-associated gastrointestinal tumorigenesis. These findings advocate clinical application of PI3K/mTORC1 inhibitors for the treatment of corresponding human malignancies.||Source Title:||Journal of Clinical Investigation||URI:||http://scholarbank.nus.edu.sg/handle/10635/110180||ISSN:||00219738||DOI:||10.1172/JCI65086|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Dec 3, 2022
WEB OF SCIENCETM
checked on Nov 23, 2022
checked on Nov 24, 2022
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.